Impact of donor-specific antibodies in reconstructive transplantation

References

• Jackson AM, Leffell MS, Montgomery RA, Zachary AA. A GPS for finding the route to transplantation for the sensitized patient. Curr. Opin. Organ. Transplant. 17(4), 433–439 (2012).
   Google Scholar
• Mengel M, Husain S, Hidalgo L, Sis B. Phenotypes of antibody-mediated rejection in organ transplants. Transpl. Int. 25(6), 611–622 (2012).
   Google Scholar
• Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant. 9(11), 2520–2531 (2009).
   PubMed Web of Science ®Google Scholar
• Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90(1), 68–74 (2010).
   PubMed Web of Science ®Google Scholar
• Morath C, Opelz G, Zeier M, Susal C. Prevention of antibody-mediated kidney transplant rejection. Transpl. Int. 25(6), 633–645 (2012).
   Google Scholar
• Morath C, Beimler J, Opelz G et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl. Int. 25(5), 506–517 (2012).
   PubMedGoogle Scholar
• Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 3(6), 708–714 (2003).
   PubMed Web of Science ®Google Scholar
• Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F. ‘Hyperacute’ renal-homograft rejection in man. N. Engl. J. Med. 279(12), 611–618 (1968).
   Google Scholar
• Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation 61(11), 1586–1592 (1996).
   PubMed Web of Science ®Google Scholar
• Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43(6), 1333–1338 (1993).
   Google Scholar
• Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am. J. Transplant. 4(1), 101–107 (2004).
   Google Scholar
• Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 8(4), 753–760 (2008).
   PubMed Web of Science ®Google Scholar
• Batal I, Lunz JG 3rd, Aggarwal N et al. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am. J. Transplant. 10(11), 2442–2452 (2010).
   Google Scholar
• Sis B, Mengel M, Haas M et al. Banff ’09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am. J. Transplant. 10(3), 464–471 (2010).
   PubMed Web of Science ®Google Scholar
• Leffell MS, Zachary AA. Anti-allograft antibodies: some are harmful, some can be overcome, and some may be beneficial. Discov. Med. 9(48), 478–484 (2010).
   Google Scholar
• Zachary AA, Montgomery RA, Locke JE, Leffell MS. Proinflammatory events and HLA antibodies. Am. J. Transplant. 10(4), 956; author reply 957 (2010).
   Google Scholar
• Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11(11), 2405–2413 (2011).
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr. Transplant. 8(6), 535–542 (2004).
   PubMedGoogle Scholar
• Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast. Reconstr. Surg. 87(3), 401–411 (1991).
   PubMed Web of Science ®Google Scholar
• Khariwala SS, Lorenz RR, Strome M. Laryngeal transplantation: research, clinical experience, and future goals. Semin. Plast. Surg. 21(4), 234–41 (2007).
   Google Scholar
• Kisu I, Banno K, Mihara M, Suganuma N, Aoki D. Uterine Transplantation: Towards Clinical Application. Gynecol. Obstet. Invest. 76(1), 74 (2013).
   Google Scholar
• Schneeberger S, Kreczy A, Brandacher G, Steurer W, Margreiter R. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am. J. Transplant. 4(8), 1372–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Bejarano PA, Levi D, Nassiri M et al. The Pathology of full-thickness cadaver skin transplant for large abdominal defects: a proposed grading system for skin allograft acute rejection. Am. J. Surg. Pathol. 28(5), 670–675 (2004).
   PubMed Web of Science ®Google Scholar
• Cendales LC, Kanitakis J, Schneeberger S et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am. J. Transplant. 8(7), 1396–1400 (2008).
   PubMed Web of Science ®Google Scholar
• Mengel M, Sis B, Haas M et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am. J. Transplant. 12(3), 563–570 (2012).
   PubMed Web of Science ®Google Scholar
• Famulski KS, Reeve J, De Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am. J. Transplant. 13(3), 634–644 (2013).
   Google Scholar
• Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr. Opin. Organ. Transplant. 15(1), 42–48 (2010).
   PubMed Web of Science ®Google Scholar
• Kanitakis J, McGregor B, Badet L et al. Absence of C4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study. Transplantation 84(2), 265–267 (2007).
   Google Scholar
• Landin L, Cavadas PC, Ibanez J, Roger I, Vera-Sempere F. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation 87(5), 776–781 (2009).
   Google Scholar
• Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81(10), 1361–1367 (2006).
   Google Scholar
• Kaufman CL, Ouseph R, Blair B et al. Graft vasculopathy in clinical hand transplantation. Am. J. Transplant 12(4), 1004–1016 (2012).
   PubMed Web of Science ®Google Scholar
• Azuma H, Tullius SG, Heemann UW, Tilney NL. Nonimmune factors may contribute to chronic rejection of kidney transplants. Transplant. Proc. 26(4), 2109–2110 (1994).
   Google Scholar
• Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ. Res. 100(7), 967–978 (2007).
   Google Scholar
• Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable HLA antigens. Curr. Opin. Organ. Transplant. 13(4), 405–410 (2008).
   Google Scholar
• Zachary AA, Delaney NL, Lucas DP, Leffell MS. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns. Hum. Immunol. 62(3), 228–235 (2001).
   Google Scholar
• Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21(8), 1398–1406 (2010).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FH, Reed EF. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens. 69 (Suppl. 1), 160–173 (2007).
   Google Scholar
• Mizutani K, Terasaki P, Hamdani E et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am. J. Transplant. 7(4), 1027–1031 (2007).
   Google Scholar
• Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70(6), 887–895 (2000).
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin. Immunol. 23(4), 224–234 (2011).
   Google Scholar
• Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86(12), 1754–1761 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89(3), 277–84 (2010).
   PubMed Web of Science ®Google Scholar
• Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 9(1), 231–235 (2009).
   Web of Science ®Google Scholar
• Lonze BE, Dagher NN, Simpkins CE et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am. J. Transplant. 10(9), 2154–2160 (2010).
   Google Scholar
• Heeger PS. A complementary approach to treating antibody-mediated transplant rejection. Kidney Int. 78(2), 125–127 (2010).
   Google Scholar
• Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1(8628), 10–12 (1989).
   PubMed Web of Science ®Google Scholar
• Bartel G, Wahrmann M, Regele H et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am. J. Transplant. 10(9), 2033–2042 (2010).
   PubMedGoogle Scholar
• Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant. Proc. 27(1), 1038–1039 (1995).
   Google Scholar
• Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365(4), 318–326 (2011).
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Law CL, Cerveny CG, Gordon KA et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin. Cancer Res. 10(23), 7842–7851 (2004).
   Google Scholar
• Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74(9), 1207–1210 (2002).
   PubMed Web of Science ®Google Scholar
• Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76(4), 730–731 (2003).
   PubMed Web of Science ®Google Scholar
• Malangoni MA, Dillon LD, Klamer TW, Condon RE. Factors influencing the risk of early and late serious infection in adults after splenectomy for trauma. Surgery 96(4), 775–783 (1984).
   Google Scholar
• Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl. Int. 25(6), 623–632 (2012).
   PubMedGoogle Scholar
• Cendales LC, Kirk AD, Moresi JM, Ruiz P, Kleiner DE. Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation 81(3), 418–422 (2006).
   PubMed Web of Science ®Google Scholar
• Kanitakis J, Jullien D, Petruzzo P et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 76(4), 688–693 (2003).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76(10), 1519–1525 (2003).
   PubMedGoogle Scholar
• Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIg desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 6(2), 346–351 (2006).
   PubMed Web of Science ®Google Scholar
• Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am. J. Transplant. 2(8), 758–760 (2002).
   PubMed Web of Science ®Google Scholar